Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 8/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534298 | 0.85 | PDPK1 (0.51) | PDPK1P2RY14 | |
| SCHEMBL12285503 | 0.85 | P2RY14 (0.43) | PDPK1P2RY14PTGER4PTPN1ALDH1A1 | |
| SCHEMBL2621644 | 0.85 | P2RY14 (0.48) | PDPK1P2RY14PTGER4ALDH1A1TSHR | |
| SCHEMBL2631928 | 0.81 | PDPK1 (0.52) | PDPK1P2RY14PTGER4ALDH1A1TSHR | |
| SCHEMBL2621702 | 0.81 | PDPK1 (0.60) | PDPK1P2RY14 | |
| SCHEMBL2621658 | 0.80 | PDPK1 (0.50) | PDPK1P2RY14PTGER4ALDH1A1TSHR | |
| SCHEMBL2621647 | 0.79 | KDM5A (0.44) | PDPK1P2RY14PTGER4PTPN1ALDH1A1 | |
| SCHEMBL5584793 | 0.78 | CNR2 (0.49) | P2RY14 | |
| SCHEMBL12182679 | 0.76 | PDPK1 (0.47) | PDPK1P2RY14PTGER4PTGS1PTGS2 | |
| SCHEMBL1926887 | 0.75 | PDE4A (0.45) | PDPK1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | PDPK1 4/4885P2RY14 3463/4885PTGER4 4820/4885 |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | PDPK1 1873/4885P2RY14 2572/4885PTGER4 1842/4885 |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | PDPK1 2768/4885P2RY14 2598/4885PTGER4 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.